Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation
Berry JL, Kogachi K, Aziz HA, McGovern K, Zolfaghari E, Murphree AL, Jubran R, Kim JW. Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation. Pediatric Blood & Cancer 2016, 64: e26270. PMID: 28221729, PMCID: PMC7034314, DOI: 10.1002/pbc.26270.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCombined Modality TherapyEtoposideEye EnucleationFemaleFollow-Up StudiesHumansInfantMaleNeoplasm Recurrence, LocalNeoplasm StagingOrbital NeoplasmsPrognosisRetinal NeoplasmsRetinoblastomaRetrospective StudiesRisk FactorsSalvage TherapyVincristineConceptsPrimary enucleation groupSystemic chemoreductionHigh-risk pathologyMetastatic diseaseOrbital recurrencePrimary enucleationAdvanced retinoblastomaEnucleation groupTreatment failureHigh-risk pathologic featuresChildren's Hospital Los AngelesPrimary outcome measureRisk of metastasisSalvage therapySecondary enucleationRetrospective reviewE retinoblastomaMedian timePathologic featuresRetinoblastoma eyesTreatment modalitiesPoor responseOutcome measuresChemoreductionSubsequent enucleation